Fig. 2.
Fig. 2. Prevention of lethal acute GVHD by KB-R7785. Lethal acute GVHD was induced by IV injection of B6 splenocytes into CBF1 mice on days 0 and 7. Ten mice in each group received IP 2 mg of KB-R7785 in 0.5% CMC (•) or 0.5% CMC (○) every day from day 0 to 20 or 0.5 mg anti-TNF MoAb (▵) on days 0 and 7. Survival (A) was monitored every day until day 28. Body weight (B) was measured at the indicated days and is indicated as the mean ± SD of 5 to 10 mice. In (B), the body weight of age-matched normal CBF1 (⋄) is also plotted.

Prevention of lethal acute GVHD by KB-R7785. Lethal acute GVHD was induced by IV injection of B6 splenocytes into CBF1 mice on days 0 and 7. Ten mice in each group received IP 2 mg of KB-R7785 in 0.5% CMC (•) or 0.5% CMC (○) every day from day 0 to 20 or 0.5 mg anti-TNF MoAb (▵) on days 0 and 7. Survival (A) was monitored every day until day 28. Body weight (B) was measured at the indicated days and is indicated as the mean ± SD of 5 to 10 mice. In (B), the body weight of age-matched normal CBF1 (⋄) is also plotted.

Close Modal

or Create an Account

Close Modal
Close Modal